

Multi-parameter Microtiter Assay to Screen Anti-HBV Agents using Primary Human Hepatocytes

Guy R. Pilkington¹, Maggie Garvey¹, Lu Yang¹, Ashlee Hawse¹, Timothy Moeller² and Robert W. Buckheit, Jr.¹,
¹ImQuest BioSciences, Inc., Frederick, MD; ²BioReclamation IVT, Baltimore, MD.

ABSTRACT


Hepatitis B virus (HBV) infection can cause both acute and chronic liver disease, with an estimated 250 million people infected, resulting in over 880,000 deaths in 2015. While an effective vaccine has been available for 35 years, the need for a viable treatment option to use in many under-developed regions of the world remains.

We had previously developed and qualified a multi-parameter microtiter assay to screen potential antiviral agents against HBV with multiple markers evaluated to demonstrate inhibitory action. This assay was developed using the chronically infected cell lines AD38 and HepG2.2.15 and has been used extensively to screen for effective antiviral agents against HBV infection. While the AD38 and HepG2.2.15 assay remains a reliable and robust assay for screening, the fact remains that utilizing chronically infected target cells renders the assay incapable of assessing agents that might result in inhibition of the early stages of the viral infection, including entry, un-coating and initial cccDNA formation.


To this end we have developed an assay using Primary Human Hepatocytes (PHH) grown in collagen-coated plates, which we infect with a virus stock (produced in-house) which has been demonstrated to provide a reproducible and efficient infection. The genotype D virus stock is derived from either AD38 or HepG2.2.15 cells, and is purified and concentrated by tangential flow filtration and ultracentrifugation to approximately 1×10^{11} genome equivalents/ml. The infected primary hepatocytes can then be used to screen for antiviral compounds targeting multiple markers of HBV infection. Given the nature of the assay, we can adjust the timing of the viral infection and compound addition such that we can assess the formation of many of the markers of HBV replication in target cells, such as early cccDNA formation, the emergence of the pre-genomic RNA (pgRNA) transcript, as well as the translation and reverse transcription products of the pgRNA. The ability to optimize the timing of the infection compared to compound addition has proved critical to the precise assessment of the emergence of particular HBV markers. The use of PHH in an infection assay most closely resembles the natural HBV infection and remains the gold standard for antiviral agent screening for both acute and chronic infection inhibitors of HBV disease.

METHODOLOGY

The antiviral activity of TDF and IFN α -2a on HBV replication in PHH was evaluated as a means of development and qualification of the microtiter assay. Cells were seeded into 48-well plates, infected with purified HBV at an MOI of 1000 and treated with serial dilutions of TDF or IFN α -2a at Day 4 post infection for a further six days. Cell culture supernatants were collected for quantification of extracellular HBV DNA and HBV antigens and the cells were lysed for evaluation of intracellular markers of viral replication.




HBV PRODUCTION



	PRE-CONCENTRATION		POST-CONCENTRATION	
	STARTING VOLUME	STARTING CONC	FINAL VOLUME	FINAL CONC
HepG2.2.15	9 L	~ 2×10^8	45 mL	~ 5×10^{10}
AD38	2 L	~ 8×10^9	10 mL	~ 3×10^{11}

MULTI-PARAMETER MICROTITER ASSAY



SUMMARY

- We are developing a broad spectrum analysis to detect and quantify multiple markers of HBV replication using Primary Human Hepatocytes.
- We are capable of producing highly infectious Hepatitis B Virus, derived from both AD38 and HepG2.2.15 cells
- Results of the examination of inhibition of HBV by control compounds using the microtiter plate assay are consistent with the molecular virology of HBV replication.
- TDF:
 - Inhibits accumulation of both intra- and extra-cellular HBV DNA
 - Does not specifically inhibit transcription of cccDNA
- IFN α -2a:
 - Inhibits accumulation of both intra- and extra-cellular HBV DNA and cccDNA